AIM Vaccine announces extraordinary general meeting

• AIM Vaccine will hold its 2026 second extraordinary general meeting in Shanghai on Sept. 7, 2026.
• Shareholders will vote on revised terms for a Domestic Unlisted Shares issuance under a specific mandate, raising the range to 40 million–80 million shares.
• The meeting will also consider resetting the issue price to RMB 1.07 per Domestic Unlisted Share.
• Approval will be sought for the Tibet Bohai subscription, covering 37,383,178 Domestic Unlisted Shares for RMB 40 million.
• Resolutions also cover the revised private issuance prospectus and removal of pre-emptive rights for the issuance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM Vaccine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12289526), on August 18, 2026, and is solely responsible for the information contained therein.